{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:29:04Z","timestamp":1761560944195,"version":"3.44.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.ahj.2004.06.002","type":"journal-article","created":{"date-parts":[[2005,1,15]],"date-time":"2005-01-15T07:30:29Z","timestamp":1105774229000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy"],"prefix":"10.1016","volume":"149","author":[{"given":"Scott J.","family":"Denardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith E.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Tcheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2004.06.002_BIB1","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/0002-9149(87)90479-6","article-title":"Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty","volume":"60","author":"Harker","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.CIR.80.1.198","article-title":"Specific platelet mediators and unstable coronary artery lesions","volume":"80","author":"Willerson","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB3","unstructured":"TracyPB. Role of platelets and leukocytes in coagulation. In: Coleman RW,Hirsh J, Marder VJ, et al, editors. Hemostasis and thrombosis: basicprinciples and clinical practice. 4th ed. Philadelphia: LippincottWilliams and Wilkins; 2001. p.575\u201396"},{"issue":"Suppl1","key":"10.1016\/j.ahj.2004.06.002_BIB4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1013236920586","article-title":"Platelet inhibition in cardiovascular disease management","volume":"5","author":"Harrington","year":"1998","journal-title":"J Thromb Thrombolysis"},{"issue":"supplII","key":"10.1016\/j.ahj.2004.06.002_BIB5","first-page":"84","article-title":"Transluminal angioplasty of coronary artery stenosis","volume":"56","author":"Gruntzig","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB6","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9149(99)80345-2","article-title":"Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb\/IIIa inhibitor during percutaneous coronary intervention","volume":"76","author":"Harrington","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI111931","article-title":"A new murine monoclonal antibody reports an activation-dependent change in the conformation and\/or microenvironment of the glycoprotein IIb\/IIIa complex","volume":"76","author":"Coller","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2004.06.002_BIB8","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood.V97.8.2314","article-title":"Antiplatelet agents in tissue factor-induced blood coagulation","volume":"97","author":"Butenas","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2004.06.002_BIB9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI118859","article-title":"Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse\/human chimeric 7E3 antibody","volume":"98","author":"Reverter","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2004.06.002_BIB10","first-page":"1231","article-title":"Antiplatelet therapy","volume":"12","author":"Calverley","year":"1998","journal-title":"Aspirin, ticlopidine\/clopidogrel, and anti-integrin agents. Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ahj.2004.06.002_BIB11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199207163270301","article-title":"Reactivation of unstable angina after the discontinuation of heparin","volume":"327","author":"Theroux","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.06.002_BIB12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0002-8703(96)90520-7","article-title":"Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty","volume":"131","author":"Smith","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.06.002_BIB13","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0735-1097(98)00696-2","article-title":"Antithrombin activity during the period of coronary revascularization","volume":"33","author":"Matthai","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/euhj.1998.1047","article-title":"Increased platelet responsiveness following coronary stenting","volume":"19","author":"Knight","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2004.06.002_BIB15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0002-9149(03)00637-4","article-title":"Relation between the degree of procedural anticoagulation and complications after coronary stent implantation","volume":"92","author":"Ashby","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0735-1097(98)00134-X","article-title":"Heparin-induced thrombocytopenia","volume":"31","author":"Brieger","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/0735-1097(94)90590-8","article-title":"Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty","volume":"23","author":"Ferguson","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0002-8703(92)90793-U","article-title":"The relationship of anticoagulation level, and the complications after successful coronary angioplasty","volume":"123","author":"McGarry","year":"1992","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2004.06.002_BIB20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/01.CIR.93.4.667","article-title":"Relationship between activated clotting time during angioplasty and abrupt closure","volume":"93","author":"Narins","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB22","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.06.002_BIB23","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","article-title":"Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention","volume":"285","author":"O'Shea","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2004.06.002_BIB24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/hc2901.093504","article-title":"Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention","volume":"104","author":"Gilchrist","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.06.002_BIB26","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2004.06.002_BIB27","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomized placebo-controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.06.002_BIB28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb\/IIIa blockade","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.06.002_BIB29","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1161\/01.CIR.0000017635.82128.8C","article-title":"Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb\/IIIa inhibitors in patients undergoing coronary stenting","volume":"105","author":"Stone","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2004.06.002_BIB30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long term therapy in patients undergoing percutaneous coronary intervention","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2004.06.002_BIB31","first-page":"631","article-title":"A randomized trial of a fixed high dose vs","volume":"18","author":"Boccara","year":"1997","journal-title":"a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J"},{"key":"10.1016\/j.ahj.2004.06.002_BIB32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/hrt.77.6.517","article-title":"Safety of low dose heparin in elective angioplasty","volume":"77","author":"Koch","year":"1997","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2004.06.002_BIB33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9149(02)02988-0","article-title":"Efficacy and safety of minimal dose (\u2264 1000 units) unfractionated heparin with abciximab in percutaneous coronary intervention","volume":"91","author":"Denardo","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB34","first-page":"23192","article-title":"The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research","volume":"44","year":"1979","journal-title":"Fed Regist"},{"key":"10.1016\/j.ahj.2004.06.002_BIB35","unstructured":"Preventionof venous thromboembolism: international consensus statement(guidelines according to clinical evidence). Int Angiol 16;1997:3\u201338"},{"key":"10.1016\/j.ahj.2004.06.002_BIB36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB37","unstructured":"GlantzSA. Primer of biostatistics. New York: McGraw-Hill; 1992. Chapter7"},{"key":"10.1016\/j.ahj.2004.06.002_BIB38","first-page":"853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention","volume":"289","author":"Lincoff","year":"2003","journal-title":"REPLACE-2 randomized trial. JAMA"},{"key":"10.1016\/j.ahj.2004.06.002_BIB39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0002-9149(01)01972-5","article-title":"Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II trial","volume":"88","author":"Blankenship","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB40","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0002-9149(02)02653-X","article-title":"Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb\/IIIa Inhibition in Stenting Trial (EPISTENT)","volume":"90","author":"Islam","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(02)02767-5","article-title":"Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention","volume":"41","author":"Tolleson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2004.06.002_BIB42","first-page":"249","article-title":"Evidence in upheaval","volume":"162","author":"Ray","year":"2002","journal-title":"Incorporating observational data into clinical practice. Arch Intern Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304003941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870304003941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:14:00Z","timestamp":1757567640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870304003941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0002870304003941"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2004.06.002","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2005,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2004.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}